Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | PNP | P00491 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.39 |
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18605583 | 0.99 | TLR7 (0.40) | TLR7HTTPNPADORA2APDE4A | |
| SCHEMBL17186383 | 0.90 | TLR9 (0.41) | TLR7PNPADORA2APDE4APDE4B | |
| Hydrochloric Acid SCHEMBL18605998 | 0.89 | TLR9 (0.40) | TLR7PNPADORA2APDE4APDE4B | |
| SCHEMBL17186252 | 0.81 | CDK2 (0.51) | MAP3K5CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL3671339 | 0.81 | DPP4 (0.44) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL667797 | 0.81 | PDE4A (0.60) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27842808 | 0.81 | PDE4A (0.53) | PNPADORA2APDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL17186345 | 0.80 | CDK2 (0.50) | MAP3K5CCNB2CDK1CCNB1CCNA2 | |
| SCHEMBL17186334 | 0.80 | CDK2 (0.46) | PNPADORA2APDE4APDE4BPDE4C | |
| SCHEMBL17186421 | 0.79 | CDK2 (0.43) | PNPADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | claimed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | claimed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | claimed |
| EP-3131877-B1 | BIGUANIDE COMPOUNDS | IMMUNOMET THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3131877-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | Immunomet Therapeutics Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015160220-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | HANALL BIOPHARMA CO., LTD. (KR) | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | TLR7 4630/4885HTT 399/4885PNP 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.